Indeed, increased fibrin deposition, paxillin, MAPK and sustained MEK2 activation, and NADPH oxidase activity promote oxidative injury and mediate neurodegeneration and synaptic dysfunction in both MS and AD6,20,43–47. The gene discussed is FMO5; the disease is myeloid sarcoma.